The demand for weight-loss medications like Wegovy and Mounjaro is soaring in the UK, with an estimated 1.6 million adults having used them in the past year, according to researchers at University College London. But as access expands – and a black market emerges – concerns are growing about patient safety and the long-term effectiveness of these powerful drugs. The increasing use of these medications, often obtained privately, is prompting calls for tighter regulation and greater clinical oversight to protect public health.
The figures, published in January 2026, reveal a significant jump in the use of glucagon-like peptide-1 (GLP-1) agonists, which work by suppressing appetite and making individuals feel fuller. The study estimates that a further 3.3 million people in England, Wales and Scotland are interested in using these drugs over the next year, far exceeding the National Health Service (NHS) England’s initial goal of prescribing them to 220,000 people over three years. This surge in demand highlights the growing societal pressure to lose weight and the appeal of a quick solution, but also raises questions about appropriate use and potential risks.
Growing Concerns Over Unregulated Access
NHS England is increasingly worried about the rise of unverified sellers and the promotion of weight-loss jabs without proper medical supervision. Dr. Claire Fuller, NHS England’s national medical director, emphasized the dangers of obtaining these medications outside of a regulated healthcare setting. “The lack of supervision can put people’s health at serious risk, and there may also be concerns about the quality or authenticity of the products on offer,” she said. “Weight-loss drugs are powerful medicines and can have serious side effects, which is why they must only be prescribed by an appropriately trained healthcare professional.”
The concern isn’t just about counterfeit products, but also about the lack of comprehensive care that should accompany these medications. The NHS stresses that access to weight-loss drugs should be coupled with “behavioural support and wraparound care,” including guidance on fine nutrition and increased physical activity. This holistic approach is designed to maximize the benefits of the medication and help patients maintain weight loss in the long term.
The Challenge of Long-Term Weight Management
While GLP-1 agonists can be highly effective for initial weight loss, maintaining that loss after stopping the medication is a significant challenge. Research from the University of Oxford has found that individuals typically regain weight within 20 months of discontinuing treatment. This underscores the importance of lifestyle changes and ongoing support to sustain weight management. The drugs are not a ‘cure’ for obesity, but rather a tool that can be effective when used as part of a broader health plan.
The UCL study also revealed demographic trends in the use of these drugs. Use was twice as common among women compared to men, and more prevalent among those aged 45-55, and individuals reporting psychological distress. Interestingly, levels of use were similar across social grades, but interest in future use was greater among more disadvantaged groups, suggesting unmet needs within these communities.
Who is Affected by the Rise in Weight-Loss Jabs?
The increasing popularity of weight-loss drugs impacts a wide range of stakeholders. Individuals struggling with obesity may uncover a potentially effective tool for weight management, but must be aware of the potential side effects and the need for long-term lifestyle changes. Healthcare professionals face the challenge of appropriately assessing patients, prescribing medications responsibly, and providing ongoing support. The NHS is grappling with managing demand, ensuring equitable access, and maintaining quality of care. And, as Dr. Fuller points out, the public at large is at risk from unregulated sources.
Professor Sarah Jackson, lead author of the UCL study from the UCL Institute of Epidemiology & Health Care, noted the scale of the phenomenon. “Our findings show that an estimated 4.9 million adults in Great Britain – nearly one in 10 – have recently used a drug to support weight loss or were interested in using one in the near future.”
Navigating the Future of Weight-Loss Medication
The NHS is actively working to address the challenges posed by the growing demand for weight-loss medications. The organization is focused on ensuring that these drugs are prescribed appropriately, with careful consideration of individual patient needs and potential risks. Further research is also needed to better understand the long-term effects of these medications and to develop more effective strategies for weight management.
As the use of weight-loss drugs continues to rise, it’s crucial for individuals to have open and honest conversations with their healthcare providers about the potential benefits and risks. Accessing these medications through legitimate channels and receiving comprehensive medical supervision is essential for ensuring safety and maximizing the chances of long-term success. The NHS emphasizes that these medications are most effective when combined with a healthy lifestyle, including a balanced diet and regular physical activity.
The next major update on the NHS’s strategy for weight-loss medication is expected in the spring of 2026, when the results of a pilot program evaluating different models of care will be released.
What are your thoughts on the increasing use of weight-loss medications? Share your comments below, and please share this article with anyone who might find it helpful.
Keep reading
